The Centers for Disease Control and Prevention (CDC) has come out with a strong recommendation for the use of Gilead Sciences’ twice-yearly HIV pre-exposure prophylaxis (PrEP) med Yeztugo, ...
The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make ...
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that lenacapavir launches at the exact time that millions of Americans lose ...
According to CDC statistics, only 25% of the approximately 1.2 million Americans who could benefit from PrEP had prescriptions in 2020. As the Bay Area Reporter has previously reported, people of ...
The HIV epidemic remains a critical public health priority in the United States. The Ending the HIV Epidemic (EHE) initiative seeks to reduce HIV diagnoses by 75% by 2025 and by 90% by 2030. Certain ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results